title: Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis.
abstract: A major deletion of the region proximal to the rearranged ABL gene on 9q was found in 14/94 (15%) of chronic myelogenous leukemia Philadelphia-positive patients by interphase fluorescent in situ hybridization with the BCR/ABL extra signal dual-color probe. Preliminary results indicated that the prognosis of the deletion 9q patients is probably worse than that of the non-deletion 9q patients. Twelve of the 14 deletion 9q patients were treated with alpha-interferon and none had a major cytogenetic response. The median duration of the chronic phase in patients not undergoing BMT was significantly shorter for the deletion 9q patients as compared to the non-deletion 9q patients (p =.0144). DNA microarray technology was performed in order to compare the gene expression patterns between the two groups of patients. A number of genes exhibiting differential expression, especially involving cell adhesion and migration, were identified. This finding may identify a sub-group of CML patients with different cell properties and a relatively poor prognosis.
authors.affiliation: Department of Pediatric Hemato-Oncology, The Chaim Sheba Medical Center, Tel-Hashomer 52621, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Cohen
authors.forename: G
authors.initials: G
authors.lastname: Rozenfeld-Granot
authors.forename: I
authors.initials: I
authors.lastname: Hardan
authors.forename: F
authors.initials: F
authors.lastname: Brok-Simoni
authors.forename: N
authors.initials: N
authors.lastname: Amariglio
authors.forename: G
authors.initials: G
authors.lastname: Rechavi
authors.forename: L
authors.initials: L
authors.lastname: Trakhtenbrot
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D017353:Gene Deletion; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics; D016313:Genes, abl; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D012333:RNA, Messenger